AstraZeneca Plc said a “careful” review of all available data of the more than 17 million people in the European Union and the U.K. it has vaccinated against so far against Covid-19 shows no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia.
The company says it is continually monitoring the safety of its vaccine.
DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.
Latest Stories
-
Heavy security at EC G/A Regional office ahead of re-collation
11 minutes -
Livestream: Newsfile probes ORAL, re-collation & transition blues
42 minutes -
Ghana-Russia Centre supports pupils of Pakro-Zongo basic school
2 hours -
Ghana launches Malaria Youth Corps, leveraging youth power in fighting malaria
3 hours -
Book Review – All’s Well (Feehi): Living a Life Guided by Grace by Abednego Okoe Feehi Amartey and Theodora Dame Adjin-Tettey
4 hours -
French for health: A new initiative by French Embassy in Ghana
10 hours -
Ghana slowly retracing steps back to path of macroeconomic stability – Deloitte
10 hours -
Ghana’s debt service-to-revenue ratio reached all-time high of 127% in 2020, highest in SSA – IMF
10 hours -
Ghana’s consolidation efforts under IMF progamme to continue to be based on revenue
11 hours -
GPL 2024/25: Hearts beat 3-1 Chelsea to return to winning ways
12 hours -
Ghana set to host second Flag All-Star Game in Accra
12 hours -
Angor CREMA: Empowering Ghana’s coastal communities for sustainable growth
13 hours -
The Legon VC… and childhood memories
13 hours -
The absurd inequality of climate work: Overcoming dilemmas in the green transition
14 hours -
ORAL team receives first dossier of ¢500m National Service ghost names scandal
14 hours